🇺🇸 FDA

Intelligence · Clinical Pipeline

BRIGHT MINDS BIOSCIENCES Pipeline

All ClinicalTrials.gov programs at BRIGHT MINDS BIOSCIENCES — phase, modality, and trial IDs.

Programs
1,063

Quick answer

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Double Trouble in Recovery

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  2. Doxazosin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  3. Doxazosin 4mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  4. Doxazosin extended release

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine or Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  5. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule active

    1 trial

  6. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule terminated

    2 trials

  7. Dronabinol 120mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Smoking

    phase 2 small molecule completed

    1 trial

  8. Dronabinol 30mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  9. Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  10. Dynorphin 1 - 13

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  11. E-cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 other completed

    1 trial

  12. EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    2 trials

  13. EVP-6124

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule terminated

    1 trial

  14. Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  15. Enzalutamide

    BRIGHT MINDS BIOSCIENCES INC.

    Prostate Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  16. Everolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  17. Evolution: Young Women Taking Charge and Growing Stronger

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  18. Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 2 other active

    1 trial

  19. Extended-Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  20. FINGER 2.0 multidomain lifestyle-based intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Cognitive Decline

    phase 2 other active

    1 trial

  21. Family Therapy based on Structural Family Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  22. Flumazenil

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule completed

    1 trial

  23. Fluorodopa F 18

    BRIGHT MINDS BIOSCIENCES INC.

    Malignant Brain Neoplasm

    phase 2 small molecule active

    1 trial

  24. Fluoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  25. Flupenthixol

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule completed

    1 trial

  26. Flupenthixol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  27. G-202

    BRIGHT MINDS BIOSCIENCES INC.

    Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  28. GSK598809

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  29. GTS-21

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule terminated

    1 trial

  30. GW468816

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  31. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 2 small molecule active

    1 trial

  32. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Benzodiazepine Dependence

    phase 2 small molecule completed

    1 trial

  33. Galantamine

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  34. Galantamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  35. Gamma hydroxybutyric

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule terminated

    1 trial

  36. Gemcitabine

    BRIGHT MINDS BIOSCIENCES INC.

    Treatment Refusal

    phase 2 small molecule active

    1 trial

  37. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  38. Gepirone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  39. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 small molecule completed

    1 trial

  40. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    2 trials

  41. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

  42. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Related Disorders

    phase 2 small molecule completed

    1 trial

  43. HEART to HAART

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  44. Heart Rate Variability Biofeedback

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Smoking

    phase 2 mab completed

    1 trial

  45. Heroin Dependence

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule terminated

    1 trial

  46. High-dose donepezil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorders

    phase 2 small molecule completed

    1 trial

  47. Hydroxycarbamid

    BRIGHT MINDS BIOSCIENCES INC.

    Central Retinal Vein Occlusion, Non-Ischemic

    phase 2 small molecule active

    1 trial

  48. IVPT

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

Frequently asked questions

How many pipeline programs does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.